SCHEMBL5956042

SCHEMBL5956042

COc1ccc(Oc2ccc(NS(C)(=O)=O)c(NS(=O)(=O)c3ccc(C)cc3)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.62
CKS1B P61024 1/20 0.58
SKP2 Q13309 1/20 0.58
CYP2C9 P11712 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
TRIM24 O15164 1/20 0.56
BRPF1 P55201 1/20 0.56
LMNA P02545 2/20 0.53
GAA P10253 1/20 0.53
MAPK1 P28482 1/20 0.53
KEAP1 Q14145 2/20 0.52
SQSTM1 Q13501 1/20 0.52
NFE2L2 Q16236 1/20 0.52
GABRG2 P18507 1/20 0.52
GABRB3 P28472 1/20 0.52
GABRA3 P34903 1/20 0.52
NFKBIA P25963 1/20 0.51
FFAR1 O14842 1/20 0.50
PGR P06401 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5956149 1.00 FFAR4 (0.62) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5955223 0.95 FFAR4 (0.68) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5956140 0.93 FFAR4 (0.62) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5955954 0.93 FFAR4 (0.62) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5956219 0.89 KEAP1 (0.63) FFAR4CKS1BSKP2TRIM24BRPF1
SCHEMBL5956187 0.87 KEAP1 (0.67) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5955298 0.87 FFAR4 (0.71) FFAR4LMNAGAAKEAP1SQSTM1
SCHEMBL5955249 0.85 FFAR4 (0.59) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5955297 0.85 FFAR4 (0.65) FFAR4CKS1BSKP2CYP2C9CYP1A2
SCHEMBL5955308 0.84 PGR (0.70) FFAR4CYP2C9CYP1A2CYP2C19TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006014405-A2 SULFONAMIDE-BASED COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-02-09 WO claimed
US-20060004197-A1 Sulfonamide-based compounds as protein tyrosine kinase inhibitors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2006-01-05 US claimed
WO-2006014405-A2 SULFONAMIDE-BASED COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-02-09 WO disclosed
US-20060004197-A1 Sulfonamide-based compounds as protein tyrosine kinase inhibitors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004197-A1 Sulfonamide-based compounds as protein tyrosine kinase inhibitors SRC, LCK, ABL1 FFAR4 3859/4885CKS1B 207/4885SKP2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.